Performance of the 2022 ACR/EULAR Classification Criteria in Comparison With the European Medicines Antibody-Associated Vasculitis

被引：0

作者：

Imai, Yuki ^{[1
]}

Ota, Yuichiro ^{[1
,2
]}

Matsumoto, Kotaro ^{[1
]}

Akiyama, Mitsuhiro ^{[1
]}

Suzuki, Katsuya ^{[1
,3
]}

Kaneko, Yuko ^{[1
]}

机构：

[1] Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol, 35 Shinanomachi,Shinju Ku, Tokyo 1608582, Japan

[2] Tokai Univ, Sch Med, Dept Internal Med, Div Rheumatol, Kanagawa 2591193, Japan

[3] Natl Hosp Org, Tokyo Med Ctr, Dept Med, Div Rheumatol, Tokyo, Japan

来源：

JOURNAL OF RHEUMATOLOGY | 2024年 / 51卷 / 12期

关键词：

antineutrophil cytoplasmic antibody-associated vasculitis; Churg-Strauss syndrome; classification; granulomatosis with polyangiitis; interstitial lung disease; microscopic polyangiitis; ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; RHEUMATOLOGY; 1990; CRITERIA; AMERICAN-COLLEGE; EOSINOPHILIC GRANULOMATOSIS; MICROSCOPIC POLYANGIITIS; LUNG-DISEASE; ALLIANCE; EPIDEMIOLOGY; PHENOTYPE;

D O I：

10.3899/jrheum.2024-0335

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

. Objective. This study aimed to compare the 2022 American College of Rheumatology (ACR)/European Methods. All consecutive, newly diagnosed patients with AAV according to the 2012 Chapel Hill Consensus Conference who visited Keio University Hospital between March 2012 and May 2022 were retrospectively reviewed. Patients were reclassified according to the EMA algorithm and the 2022 ACR/EULAR criteria, and their clinical characteristics were statistically analyzed. Results. A total of 114 patients with AAV were included in the analyses. Using the EMA algorithm as a reference, reclassification of the patients revealed sensitivity and specificity of the 2022 ACR/EULAR criteria of 100% and 96% for eosinophilic granulomatosis with polyangiitis, 40% and 97% for granulomatosis with polyangiitis (GPA), and 90% and 49% for microscopic polyangiitis (MPA), respectively. Approximately half of patients classified as EMA-GPA or EMA-unclassifiable were reclassified as 2022-MPA; these patients were older, were more disposed to be positive for myeloperoxidase (MPO)-ANCA, and had interstitial lung disease (ILD) more frequently than patients with 2022-GPA or non-2022-MPA. Further, some patients positive for MPO-ANCA with biopsy-proven granulomatous inflammation were also reclassified from EMA-GPA to 2022-MPA. Over the mean observation period of 4.0 years, 16 patients died. Overall survival for each classification group differed significantly from the 2022 ACR/EULAR criteria (P = 0.02), but not with the EMA algorithm (P = 0.21). Conclusion. Among the patients classified as EMA-GPA or EMA-unclassifiable, older patients with MPO-ANCA and ILD tended to be reclassified as 2022-MPA. The 2022 ACR/EULAR criteria were more useful in prognostic prediction than the EMA algorithm.

引用

页码：1102 / 1110

页数：9

共 30 条

[1]

Jennette JC, Falk RJ, Bacon PA, Et al., 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, Arthritis Rheum, 65, pp. 1-11, (2013)

[2]

Masi AT, Hunder GG, Lie JT, Et al., The American College of Rheumatology 1990 criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis), Arthritis Rheum, 33, pp. 1094-1100, (1990)

[3]

Leavitt RY, Fauci AS, Bloch DA, Et al., The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis, Arthritis Rheum, 33, pp. 1101-1107, (1990)

[4]

Watts R, Lane S, Hanslik T, Et al., Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies, Ann Rheum Dis, 66, pp. 222-227, (2007)

[5]

Grayson PC, Ponte C, Suppiah R, Et al., 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis, Arthritis Rheumatol, 2022, 74, pp. 386-392

[6]

Robson JC, Grayson PC, Ponte C, Et al., 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis, Arthritis Rheumatol, 2022, 74, pp. 393-399

[7]

Suppiah R, Robson JC, Grayson PC, Et al., 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis, Arthritis Rheumatol, 2022, 74, pp. 400-406

[8]

Sada K, Kaname S, Higuchi T, Et al., Validation of new ACR/EULAR 2022 classification criteria for anti-neutrophil cytoplasmic antibody-associated vasculitis, Mod Rheumatol, 34, pp. 144-150, (2023)

[9]

Pyo JY, Lee LE, Park YB, Lee SW., Comparison of the 2022 ACR/EULAR classification criteria for antineutrophil cytoplasmic antibody-associated vasculitis with previous criteria, Yonsei Med J, 64, pp. 11-17, (2023)

[10]

Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW., The reclassification of patients with previously diagnosed eosinophilic granulomatosis with polyangiitis based on the 2022 ACR/EULAR criteria for antineutrophil cytoplasmic antibody-associated vasculitis, J Rheumatol, 50, pp. 213-218, (2023)

← 1 2 3 →